Oppenheimer lowered the firm’s price target on RxSight to $65 from $72 and keeps an Outperform rating on the shares following quarterly results. Looking ahead, RxSight’s plan for international expansion is upside to the firm’s estimate as is use of the company’s strong balance sheet for growth investments in sales/marketing and R&D, Oppenheimer says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST: